What it sells
Molecular data for drug development from microbial genomes.
Business model breakdown
Buyer: who owns the budget?
UnverifiedDrug-discovery teams at pharma/biotech seeking library access (site CTA: 'Discuss library access').
Trigger: what makes them buy now?
Need new chemical starting points beyond familiar chemistry for first-in-class medicines.
Workflow: what inputs become what output?
Curate microbes with rare biosynthetic instructions, capture them in parallel, screen enriched extracts first, then produce hits in engineered hosts for resupply.
Distribution: how it reaches customers
Business development via meetings at conferences (EFMC-ISMC, ELRIG, ABIM) and contact form; Paris lab.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-04-02 | — | €20M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.